Clinical significance of p16^INK4A and p14^ARF promoter methylation in renal cell carcinoma: a meta-analysis.

ABSTRACT: The inactivation of p16^INK4A and p14^ARF via promoter methylation has been investigated in various cancers. However, the clinical effects of p16^INK4A and p14^ARF promoter methylation on renal cell carcinoma (RCC) remain to be clarified. The pooled data were calculated and summarized. Finally, an investigation of 14 eligible studies with 1231 RCC patients and 689 control patients was performed. Methylated p16^INK4A and p14^ARF were observed to be significantly higher in RCC than in control subjects without malignancies (OR = 2.77, P = 0.005; OR = 11.73, P < 0.001, respectively). Methylated p16^INK4A was significantly associated with the risk of RCC in the tissue subgroup,

SUBMITTER: Ren Y 

PROVIDER: S-EPMC5610010 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature